{"abstracts":[{"sha1":"e4f85c4e2edb7c812a5dca1f0dd9343a6f8292af","content":"ABSTRACTAlthough over 12 billion COVID-19 vaccine doses have been administered globally, the important issue of whether the optimal doses are being used has been relatively neglected. To address this question, we reviewed the reports of early-phase dose-finding trials of the nine COVID-19 vaccines approved by World Health Organization (and one additional vaccine which showed partial clinical efficacy), extracting information on study design and findings on reactogenicity and early humoral immune response. The number of different doses evaluated per vaccine varied widely (range 1-7), as did the number of subjects studied per dose (range 15-190). As expected, the frequency and severity of adverse reactions generally increased at higher doses, although most were clinically tolerable. Higher doses also tended to elicit better immune responses, but differences between the maximum dose and the second-highest dose evaluated were small, typically less than 1.6-fold for both binding antibody concentration and neutralising antibody titre. All of the trials had at least one important design limitation: few doses evaluated, large gaps between adjacent doses, or an inadequate sample size. In general, it is therefore uncertain whether the single dose taken into clinical efficacy trials, and subsequently authorised by regulatory agencies, was optimal. In particular, the recommended doses for some vaccines appear to be unnecessarily high. Although reduced dosing for booster injections is an active area of research, the priming dose is equally deserving of study. We conclude by suggesting some ways in which the design of future trials of candidate COVID-19 vaccines could be improved.","mimetype":"application/xml+jats"}],"refs":[{"index":0,"extra":{"unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations 2021 [Available from: https://ourworldindata.org/covid-vaccinations."},"key":"2022092407200812000_2022.09.20.22276701v1.1"},{"index":1,"extra":{"doi":"10.1016/s1473-3099(21)00344-3"},"key":"2022092407200812000_2022.09.20.22276701v1.2"},{"index":2,"extra":{"doi":"10.1038/s41591-021-01440-4","volume":"27"},"key":"2022092407200812000_2022.09.20.22276701v1.3","year":2021,"container_name":"Nat Med","title":"Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality","locator":"1321"},{"index":3,"extra":{"doi":"10.3386/w29180","unstructured":"Wiecek W , Ahuja A , Chaudhuri E , Kremer M , Gomes AS , Suyder C , et al. Testing fractional doses of COVID-19 vaccines. National Bureau of Economic Research Working Paper Series.; 2021 October 2021. Report No.: Working Paper 29180."},"key":"2022092407200812000_2022.09.20.22276701v1.4"},{"index":4,"extra":{"unstructured":"CEPI opens call to evaluate fractional COVID-19 booster and third shots as part of efforts to stretch global vaccine supply [press release]. 2021."},"key":"2022092407200812000_2022.09.20.22276701v1.5"},{"index":5,"extra":{"unstructured":"World Health Organization. COVID-19 Vaccine Tracker [Available from: https://covid19.trackvaccines.org/agency/who/."},"key":"2022092407200812000_2022.09.20.22276701v1.6"},{"index":6,"extra":{"doi":"10.1016/s1473-3099(21)00677-0","volume":"22"},"key":"2022092407200812000_2022.09.20.22276701v1.7","year":2022,"container_name":"Lancet Infect Dis","title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial","locator":"329"},{"index":7,"extra":{"doi":"10.1056/nejmoa2027906"},"key":"2022092407200812000_2022.09.20.22276701v1.8"},{"index":8,"extra":{"doi":"10.1056/nejmoa2022483","issue":"20","volume":"383"},"key":"2022092407200812000_2022.09.20.22276701v1.9","year":2020,"container_name":"N Engl J Med","title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","locator":"1920"},{"index":9,"extra":{"doi":"10.1080/22221751.2021.2004866"},"key":"2022092407200812000_2022.09.20.22276701v1.10"},{"index":10,"extra":{"doi":"10.1016/s0140-6736(20)31604-4"},"key":"2022092407200812000_2022.09.20.22276701v1.11"},{"index":11,"extra":{"doi":"10.1056/nejmoa2034201","issue":"19","volume":"384"},"key":"2022092407200812000_2022.09.20.22276701v1.12","year":2021,"container_name":"N Engl J Med","title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","locator":"1824"},{"index":12,"extra":{"doi":"10.1016/s0140-6736(20)31605-6"},"key":"2022092407200812000_2022.09.20.22276701v1.13"},{"index":13,"extra":{"doi":"10.1056/nejmoa2026920"},"key":"2022092407200812000_2022.09.20.22276701v1.14"},{"index":14,"extra":{"doi":"10.1016/s1473-3099(20)30843-4","volume":"21"},"key":"2022092407200812000_2022.09.20.22276701v1.15","year":2021,"container_name":"Lancet Infect Dis","title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial","locator":"181"},{"index":15,"extra":{"doi":"10.1016/s1473-3099(20)30831-8"},"key":"2022092407200812000_2022.09.20.22276701v1.16"},{"index":16,"extra":{"doi":"10.1016/s1473-3099(21)00070-0","volume":"21"},"key":"2022092407200812000_2022.09.20.22276701v1.17","year":2021,"container_name":"Lancet Infect Dis","title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","locator":"950"},{"index":17,"extra":{"doi":"10.1001/jamanetworkopen.2021.43955"},"key":"2022092407200812000_2022.09.20.22276701v1.18","year":2022,"container_name":"JAMA Netw Open","title":"Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis","locator":"e2143955"},{"index":18,"extra":{"doi":"10.1517/14712598.2010.519332"},"key":"2022092407200812000_2022.09.20.22276701v1.19"},{"index":19,"extra":{"doi":"10.1016/s0140-6736(20)32661-1"},"key":"2022092407200812000_2022.09.20.22276701v1.20"},{"index":20,"extra":{"doi":"10.1038/s41577-020-00471-1"},"key":"2022092407200812000_2022.09.20.22276701v1.21"},{"index":21,"extra":{"doi":"10.1126/science.abm3425","issue":"6576","volume":"375"},"key":"2022092407200812000_2022.09.20.22276701v1.22","year":2022,"container_name":"Science","title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","locator":"43"},{"index":22,"extra":{"doi":"10.1002/sim.3802"},"key":"2022092407200812000_2022.09.20.22276701v1.23"},{"index":23,"extra":{"doi":"10.1080/10543406.2020.1730874","volume":"30"},"key":"2022092407200812000_2022.09.20.22276701v1.24","year":2020,"container_name":"Journal of biopharmaceutical statistics","title":"Design optimization for dose-finding trials: a review","locator":"662"},{"index":24,"extra":{"doi":"10.1016/j.vaccine.2021.02.007"},"key":"2022092407200812000_2022.09.20.22276701v1.25"},{"index":25,"extra":{"unstructured":"UNICEF. COVID-19 Vaccine Market Dashboard [Available from: https://www.unicef.org/supply/covid-19-vaccine-market-dashboard."},"key":"2022092407200812000_2022.09.20.22276701v1.26"},{"index":26,"extra":{"unstructured":"Alignment with ICMRA consensus on immunobridging for authorising new COVID-19 vaccines [press release]. 15 September 2021."},"key":"2022092407200812000_2022.09.20.22276701v1.27"},{"index":27,"extra":{"doi":"10.1093/biostatistics/3.1.51"},"key":"2022092407200812000_2022.09.20.22276701v1.28"},{"index":28,"extra":{"doi":"10.1016/s0140-6736(21)02717-3","issue":"10318","volume":"398"},"key":"2022092407200812000_2022.09.20.22276701v1.29","year":2021,"container_name":"Lancet","title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","locator":"2258"},{"index":29,"extra":{"unstructured":"Moderna COVID-19 vaccine [press release]. 2021."},"key":"2022092407200812000_2022.09.20.22276701v1.30"},{"index":30,"extra":{"unstructured":"U.S.Pharmacist. FDA Considering Boosters Mid-Month for Other Authorized COVID-19 Vaccines 2021 [Available from: https://www.uspharmacist.com/article/fda-considering-boosters-midmonth-for-other-authorized-covid19-vaccines."},"key":"2022092407200812000_2022.09.20.22276701v1.31"},{"index":31,"extra":{"doi":"10.1016/s0140-6736(13)62556-8","issue":"9927","volume":"383"},"key":"2022092407200812000_2022.09.20.22276701v1.32","year":2014,"container_name":"Lancet","title":"Antiretroviral dose reduction: good for patients and rollout","locator":"1442"}],"contribs":[{"index":0,"creator_id":"ch4eolp74zakxh4y6wd5aqs4kq","creator":{"orcid":"0000-0003-1836-4446","surname":"Dunn","given_name":"David","display_name":"David Dunn","state":"active","ident":"ch4eolp74zakxh4y6wd5aqs4kq","revision":"735bd4a5-925a-4e90-933f-5d78d0eb0c22"},"raw_name":"David Dunn","given_name":"David","surname":"Dunn","role":"author","extra":{"seq":"first"}},{"index":1,"raw_name":"Richard Gilson","given_name":"Richard","surname":"Gilson","role":"author"},{"index":2,"raw_name":"Sheena McCormack","given_name":"Sheena","surname":"McCormack","role":"author"},{"index":3,"raw_name":"Laura McCoy","given_name":"Laura","surname":"McCoy","role":"author"}],"publisher":"Cold Spring Harbor Laboratory","ext_ids":{"doi":"10.1101/2022.09.20.22276701"},"release_year":2022,"release_date":"2022-09-22","release_type":"post","work_id":"zh2hp26tjjfzdas647voomxzae","title":"Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials","revision":"2ad5aad3-6072-47a7-acf8-68d93b800ffc","extra":{"crossref":{"type":"posted-content"}}}